The DOI matches its Crossref record.
The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
Abstract
This study evaluated the efficacy and safety of donepezil in patients with mild to moderately severe Alzheimer''s disease, and examined the relationships between plasma donepezil concentration, red blood cell acetylcholinesterase (AChE) activity and clinical response. The trial was of a multicenter, double-blind, parallel-group design and patients were randomised to once-daily treatment with either donepezil (1, 3 or 5 mg) or placebo. The 12-week double-blind phase was followed by a 2-week single-blind placebo washout. 161 patients (55-85 years of age) entered the study and 141 completed treatment. Patients treated with donepezil showed dose-related improvements in the Alzheimer''s Disease Assessment Scale - cognitive subscale score (ADAS-cog) and in MMSE scores. The improvements in ADAS-cog were statistically significantly greater with donepezil 5 mg/day than with placebo. There was a 50% reduction in the percentage of patients showing clinical decline with donepezil at 5 mg/day (11%) relative to placebo (20%). In addition, a statistically significant correlation between plasma concentrations of donepezil and AChE inhibition was demonstrated. A plateau of inhibition (76-84%) was reached at plasma donepezil concentrations >50 ng/ml. The correlation between plasma drug concentrations and ADAS-cog (p = 0.014), MMSE (p = 0.023) and patient quality of life scores, assessed by the patient (p = 0.037) were also statistically significant, as was the correlation between AChE inhibition and change in ADAS-cog (p = 0.008). The incidence of treatment-emergent adverse events with all three dosages of donepezil (64-68%) was comparable to that observed with placebo (65%). Donepezil had no clinically significant effect on vital signs, haematology or clinical biochemistry tests. Importantly, donepezil was not associated with any hepatotoxicity, as observed with acridine-based cholinesterase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
The Hawthorne Effect: a randomised, controlled trial
McCarney, R., Warner, J., Iliffe, S., van Haselen, R., Griffin, M., & Fisher, P. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-30 · Cited by 1,715
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Self-citationConsensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
Callahan, C. M., Boustani, M. A., Unverzagt, F. W., Austrom, M. G., Damush, T. M., Perkins, A. J., Fultz, B. A., Hui, S. L., Counsell, S. R., & Hendrie, H. C. (2006) · JAMA · doi:10.1001/jama.295.18.2148 · Cited by 798
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790
Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 773
Self-citationRaina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
Acetylcholine in mind: a neurotransmitter correlate of consciousness?
Perry, E., Walker, M., Grace, J., & Perry, R. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01361-7 · Cited by 763
Smith, S., Lamping, D., Banerjee, S., Harwood, R., Foley, B., Smith, P., Cook, J., Murray, J., Prince, M., Levin, E., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9100 · Cited by 639
Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 626
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Cholinesterase inhibitors as Alzheimer's therapeutics (Review)
Sharma, K. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10374 · Cited by 602
The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1
Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Möller, H.-J., Rogers, S. L., & Friedhoff, L. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017126 · Cited by 580
Self-citationKaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities
Cummings, J. L., Vinters, H. V., Cole, G. M., & Khachaturian, Z. S. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s2 · Cited by 519
The Detection of Dementia in the Primary Care Setting
Valcour, V. G., Masaki, K. H., Curb, J. D., & Blanchette, P. L. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.19.2964 · Cited by 498
Perry, R. J., Watson, P., & Hodges, J. R. (2000) · Neuropsychologia · doi:10.1016/s0028-3932(99)00079-2 · Cited by 494
A 7 Minute Neurocognitive Screening Battery Highly Sensitive to Alzheimer's Disease
Solomon, P. R., Hirschoff, A., Kelly, B., Relin, M., Brush, M., DeVeaux, R. D., & Pendlebury, W. W. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.349 · Cited by 418
Lin, J. S., O’Connor, E., Rossom, R. C., Perdue, L. A., & Eckstrom, E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-9-201311050-00730 · Cited by 410
The cholinergic system in Alzheimer's disease
Kása, P., Rakonczay, Z., & Gulya, K. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00028-2 · Cited by 409
Treatment of Alzheimer's Disease
Mayeux, R., & Sano, M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911253412207 · Cited by 385
Cholinesterase Inhibitors: A New Class of Psychotropic Compounds
Cummings, J. L. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.4 · Cited by 384
Nordberg, A., & Svensson, A.-L. (1998) · Drug Safety · doi:10.2165/00002018-199819060-00004 · Cited by 381
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
Structural roles of acetylcholinesterase variants in biology and pathology
Grisaru, D., Sternfeld, M., Eldor, A., Glick, D., & Soreq, H. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00693.x · Cited by 355
Qaseem, A., Snow, V., Cross, J. T., Forciea, M. A., Hopkins, R., Shekelle, P., Adelman, A., Mehr, D., Schellhase, K., Campos-Outcalt, D., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00008 · Cited by 354
Practice parameter: Management of dementia (an evidence-based review)
Oken, B. S. (2001) · Neurology · doi:10.1212/wnl.57.12.2323 · Cited by 351
Current Pharmacotherapy for Alzheimer's Disease
Lleó, A., Greenberg, S. M., & Growdon, J. H. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131442 · Cited by 345
Coyle, J., & Kershaw, P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 335
Acetylcholinesterase inhibitors in Alzheimer’s disease
McGleenon, Dynan, & Passmore (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00026.x · Cited by 317
Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease
Geldmacher, D. S., Provenzano, G., McRae, T., Mastey, V., & Ieni, J. R. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1365-2389.2003.51306.x · Cited by 313
Patnode, C. D., Perdue, L. A., Rossom, R. C., Rushkin, M. C., Redmond, N., Thomas, R. G., & Lin, J. S. (2020) · JAMA · doi:10.1001/jama.2019.22258 · Cited by 309
Quality of life in dementia patients in long-term care
Gonz�lez-Salvador, T., Lyketsos, C. G., Baker, A., Hovanec, L., Roques, C., Brandt, J., & Steele, C. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(200002)15:2<181::aid-gps96>3.0.co;2-i · Cited by 294
Rogers, S. L., & Friedhoff, L. T. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00079-5 · Cited by 292
Self-citationStructural and kinetic features of amyloid β-protein fibrillogenesis: Review
Teplow, D. B. (1998) · Amyloid · doi:10.3109/13506129808995290 · Cited by 283
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
Rockwood, K. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.5.589 · Cited by 279
the EVIDEM-ED project, Koch, T., & Iliffe, S. (2010) · BMC Family Practice · doi:10.1186/1471-2296-11-52 · Cited by 275
The Cholinergic Hypothesis of Neuropsychiatric Symptoms in Alzheimer's Disease
Cummings, J. L., & Back, C. (1998) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199821001-00009 · Cited by 274
Ravina, B. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.050682 · Cited by 273
Newhouse, P. A., Potter, A., & Levin, E. D. (1997) · Drugs & Aging · doi:10.2165/00002512-199711030-00005 · Cited by 267
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266
Rogers, S. L., Doody, R. S., Pratt, R. D., & Ieni, J. R. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00067-5 · Cited by 265
Self-citationHolland, A. J., Hon, J., Huppert, F. A., & Stevens, F. (2000) · Journal of Intellectual Disability Research · doi:10.1046/j.1365-2788.2000.00263.x · Cited by 259
Seltzer, B. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.7.1011 · Cited by 256
Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease
Lopez, O. L. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.3.310 · Cited by 255
Placebo effects: clinical aspects and neurobiology
Oken, B. S. (2008) · Brain · doi:10.1093/brain/awn116 · Cited by 237
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219
Cholinesterase Inhibitors and Beyond
Pepeu, G., & Giovannini, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602861 · Cited by 209
(1999) · Europe PMC (PubMed Central) · Cited by 205
Kaneko, N., Okano, H., & Sawamoto, K. (2006) · Genes to Cells · doi:10.1111/j.1365-2443.2006.01010.x · Cited by 202
Pragmatic randomised controlled trials in psychiatry
Hotopf, M., Churchill, R., & Lewis, G. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.3.217 · Cited by 165
The P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
Animal models of Alzheimer disease: historical pitfalls and a path forward
Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132
Parnetti, L., Mignini, F., Tomassoni, D., Traini, E., & Amenta, F. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.043 · Cited by 122
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease
Thompson, S., Lanctôt, K. L., & Herrmann, N. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.425 · Cited by 109
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00678-3 · Cited by 103
Wilkinson, D., Stave, C., Keohane, D., & Vincenzino, O. (2004) · Journal of International Medical Research · doi:10.1177/147323000403200207 · Cited by 99
Behavior and Treatment in Frontotemporal Dementia
Perry, R. J., & Miller, B. L. (2001) · Neurology · doi:10.1212/wnl.56.suppl_4.s46 · Cited by 90
Traini, E., Bramanti, V., & Amenta, F. (2013) · Current Alzheimer Research · doi:10.2174/15672050113106660173 · Cited by 78
Leveraging the cortical cholinergic system to enhance attention
Demeter, E., & Sarter, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.060 · Cited by 75
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
The Relationship Between Donepezil and Behavioral Disturbances in Patients With Alzheimer's Disease
Cummings, J. L., Donohue, J. A., & Brooks, R. L. (2000) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200005000-00008 · Cited by 71
Systematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors
Leinonen, A., Koponen, M., & Hartikainen, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124500 · Cited by 64
Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
Caltagirone, C., Bianchetti, A., Luca, M. D., Mecocci, P., Padovani, A., Pirfo, E., Scapicchio, P., Senin, U., Trabucchi, M., & Musicco, M. (2005) · Drugs & Aging · doi:10.2165/00002512-200522001-00002 · Cited by 55
Balducci, C., Nurra, M., Pietropoli, A., Samanin, R., & Carli, M. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1385-7 · Cited by 42
(2000) · doi:10.1002/1531-8249(200012)48:6
Metadata
- Authors
- Rogers, S. L., & Friedhoff, L. T.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 1996
- Volume
- 7
- Issue
- 6
- Pages
- 293-303
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W1994197596
- Cited by
- 742
- References
- 0
- FWCI
- 58.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.